This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Pre-Markets Mixed Despite Strong Earnings Results
by Zacks Equity Research
Pre-Markets Mixed Despite Strong Earnings Results.
Morning Headlines Defy Expectations, but Pre-Markets Sell
by Mark Vickery
Only the tech-heavy (AI-trade-heavy) Nasdaq is in the green at this hour.
Wall Street's Insights Into Key Metrics Ahead of UnitedHealth (UNH) Q2 Earnings
by Zacks Equity Research
Evaluate the expected performance of UnitedHealth (UNH) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching UnitedHealth (UNH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
by Urmimala Biswas
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
Humana (HUM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
by Moumi Mondal
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
Analysts Estimate UnitedHealth Group (UNH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
UnitedHealth (UNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth Group (UNH) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed the most recent trading day at $282.65, moving 1.88% from the previous trading session.
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
by Moumi Mondal
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, UnitedHealth Group (UNH) closed at $300.58, marking a -1.16% move from the previous day.
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
by Urmimala Biswas
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
UnitedHealth's Commercial Unit: A Stabilizer Amid Healthcare Turmoil?
by Zacks Equity Research
UNH relies on its growing commercial insurance business as pressures from Medicare mount and industry headwinds persist.
UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?
by Kaibalya Pravo Dey
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
Is UnitedHealth (UNH) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in UnitedHealth (UNH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
UnitedHealth (UNH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Billing or Healing? UnitedHealth's HouseCalls Get a DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a DOJ criminal probe over its HouseCalls billing, raising stakes for the Medicare Advantage giant.
Company News for Jul 10, 2025
by Zacks Equity Research
Companies in The News Are: AMZN, BA, PLTR, UNH
Is CVS Moving Closer to Reaching Its Long-Term Low 3X Leverage Goal?
by Moumi Mondal
CVS Health inches closer to its long-term leverage target, helped by Aetna margin recovery and disciplined cash use.
UnitedHealth Group (UNH) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
UnitedHealth Group (UNH) concluded the recent trading session at $307.7, signifying a +1.31% move from its prior day's close.
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
by Kaibalya Pravo Dey
MOH slashes 2025 EPS outlook by more than 10%, citing rising medical costs and echoing warnings from CNC and UnitedHealth.
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
by Kaibalya Pravo Dey
UNH and peers tumble as Medicaid cuts, enrollment shifts and rising costs shake up the managed care sector.
UnitedHealth Group (UNH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, UnitedHealth Group (UNH) closed at $307.56, marking a -5.7% move from the previous day.
UnitedHealth Dropped From Russell Growth: How to Trade UNH Now
by Kaibalya Pravo Dey
UNH's removal from key Russell growth indices caps a turbulent stretch marked by steep losses, rising costs and regulatory woes.
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.